Botryodiplodin is a fungal metabolite isolated from the endophytic fungus *Botryodiplodia theobromae*. It has shown promising biological activity, particularly as an anti-cancer agent. Its synthesis involves complex organic chemistry steps, and its mechanism of action involves interfering with the cell cycle and inducing apoptosis. The study of botryodiplodin focuses on its potential as a novel anti-cancer drug, with research exploring its effectiveness against various types of cancer cells. Its structural complexity and unique biological activity make it a promising candidate for further drug development.'
botryodiplodin: antibiotic with antileukemic activity; isolated from Botryodiplodia theobromae Pat.; has interesting property of turning the skin of the individual various shades of pink 2-3 hrs after application; toxic metabolite of Penicillium carneo-lutescens; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 33701 |
| CHEMBL ID | 2007203 |
| CHEBI ID | 168857 |
| SCHEMBL ID | 11573930 |
| MeSH ID | M0049542 |
| Synonym |
|---|
| 1-(5-hydroxy-4-methyloxolan-3-yl)ethanone |
| CHEBI:168857 |
| botrydiplodin |
| botryodipolodin |
| nsc114342 |
| botyrodiplodin |
| 27098-03-9 |
| botryodiplodin |
| nsc157390 , |
| botryodiplodin (synthetic) |
| cytostipin |
| 1-(tetrahydro-5-hydroxy-4-methyl-3-furanyl)ethanone |
| antibiotic psx 1 |
| nsc 114342 |
| brn 2935786 |
| ketone, methyl tetrahydro-5-hydroxy-4-methyl-3-furyl |
| methyltetrahydro-5-hydroxy-4-methyl-3-furyl-ketone |
| ethanone, 1-(tetrahydro-5-hydroxy-4-methyl-3-furanyl)- |
| 2-hydroxy-3-methyl-4-acetyltetrahydrofurane |
| 2-hydroxy-3-methyl-4-acetyltetrahydrofuran |
| NCI60_001142 |
| AKOS006280158 |
| unii-5g35q22r8m |
| 113531-94-5 |
| psx 1 |
| SCHEMBL11573930 |
| CHEMBL2007203 |
| 1-(5-hydroxy-4-methyloxolan-3-yl)ethan-1-one |
| 4-acetyl-2-hydroxy-3-methyltetrahydrofuran |
| 1-(tetrahydro-5-hydroxy-4-methyl-3-furanyl)ethanone, 9ci |
| 1-(tetrahydro-5-hydroxy-4-methyl-3-furanyl)-ethanone |
| Q15410293 |
| 1-(5-hydroxy-4-methyltetrahydrofuran-3-yl)ethan-1-one |
| 1-(5-hydroxy-4-methyltetrahydrofuran-3-yl)ethanone |
| STARBLD0006471 |
| Class | Description |
|---|---|
| oxolanes | Any oxacycle having an oxolane (tetrahydrofuran) skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (76.92) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||